GlassScriptPhysician profile
Jennifer Wurst
NPI 1275510166
$1,626.09
in general payments reported to CMS, 2019-2025
23 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $101 · 2023: $501 · 2024: $570 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.51 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $389.27 | 2023-2025 | Ubrelvy, Vraylar, Qulipta |
| Exact Sciences Corporation | $197.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $147.28 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $133.68 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $110.70 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $93.07 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $88.07 | 2023-2025 | |
| Lilly USA, LLC | $85.70 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.47 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $46.46 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $35.85 | 2024 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.34 | 2022-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $28.93 | 2023-2024 | Gardasil 9, Gardasil, Dificid |
| Xeris Pharmaceuticals, INC. | $24.78 | 2023 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $24.22 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $21.09 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Sanofi Pasteur INC. | $17.08 | 2023 | |
| Echosens North America, INC. | $16.28 | 2025 | Fibroscan |
| Abbott Laboratories | $15.79 | 2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $15.30 | 2025 | Unithroid |
| Amgen INC. | $14.89 | 2025 | Repatha |
| Phathom Pharmaceuticals, INC. | $13.43 | 2024 | Voquezna |
| Lundbeck LLC | $13.29 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.